17 results about "Streptococcus infection" patented technology

The invention relates to a fusion protein, an immunogenic composition and a recombinant degenerate vaccine for preventing and treating infection of various pathogenic streptococci, as well as a molecular architecture design, application and the like. According to the invention, three immune antigens, namely an elongation factor Tu (Tuf), a molecular chaperone DnaK and an elongation factor G (fusA), are screened, and it is proved that fusion protein molecules of the three antigens can significantly inhibit tissue lesions caused by infection of different serotypes and different types of streptococci, have good immunogenicity, play roles in immune protection and effective prevention and treatment, and have good application prospects. The bacillus subtilis has the characteristics of broad-spectrum and high-efficiency prevention of streptococcus bacterial infection, and has a wide application prospect.

The invention relates to the technical field of biology and new medicine, in particular to a preparation method, an identification method and a histopathologic analysis method of a rat uterus scar diverticulum model. The preparation method of the rat uterus scar diverticulum model comprises the following steps: sequentially simulating rat pregnancy by using female progestational hormone, and infecting a uterus incision by using group B streptococcus (GBS) to obtain the rat uterus scar diverticulum model. The preparation method comprises the following steps: constructing a pseudopregnant rat model; preparing a GBS bacterial solution with a certain concentration, and immersing 3-0 silk threads with the length of about 1cm into the bacterial solution for 24 hours for later use; an incision with the length of about 2 cm is formed in the uterus on the two sides of the rat, and the incision is sutured discontinuously by an absorbable line. The simulated pregnant mouse is used, the influence of uterine hyperemia during human delivery and hormone change after female progestational hormone withdrawal on the uterine microenvironment is met, the formation of the human uterine scar diverticulum simulated by using the group B streptococcus infection incision is related to cesarean delivery incision infection, and therefore the success rate of the obtained model is high.

The present invention provides a Lactiplantibacillus plantarum strain capable of resisting Streptococcus pneumoniae infection in the respiratory tract, with a deposit number of CCTCC NO: M2022359. The Lactiplantibacillus plantarum VHProbi P06 strain provided by the present invention has a strong adhesion effect on nasal epithelial cells and can colonize in the nasal cavity; and can significantly inhibit the adhesion effect of Streptococcus pneumoniae, the main pathogenic microorganism of sinusitis, on nasal epithelial cells; it also has an inhibitory effect on the growth of most other pathogenic microorganisms of sinusitis, including β-hemolytic streptococcus, Streptococcus pyogenes, Escherichia coli, Staphylococcus aureus, etc. The Lactiplantibacillus plantarum VHProbi P06 strain provided by the present invention has no toxic effect on the body and has good safety. It can be added to drugs for preventing respiratory diseases or improving respiratory symptoms caused by bacterial infections, and has broad application prospects.

The present invention relates to a fusion protein, immunogenic composition, recombinant vaccine, and molecular architecture design and application, etc., for the prevention of Streptococcus Pneumoniae infection. The present invention starts from the protein molecular tertiary structures of ply and PhtD, and via creatively screening, the C-terminal domain of ply protein and the N-terminal domain of phtD protein are finally selected to construct a fusion protein, and the elements such as Fc domain and STABILON are further added. The fusion protein molecule of the present invention can weaken tissue lesions caused by Streptococcus Pneumoniae infection, has good immunogenicity, has an effective preventive and immunoprotective effect, and efficiently prevents Streptococcus Pneumoniae infection. The immunogenic composition, fusion protein, and recombinant vaccine for preventing Streptococcus Pneumoniae infection of the present invention have broad application prospects.

Methods of predicting survival following Streptococcus iniae infection in tilapia, the method comprising determining the alleles present at one or more, optionally two or more, DNA polymorphism in the tilapia and predicting whether or not the tilapia will survive Streptococcus iniae infection based on the determination of the alleles, methods of detecting in a sample from a tilapia the presence or absence of the alleles present at one or more, optionally two or more, DNA polymorphism associated with survival following Streptococcus iniae infection, relating methods of obtaining an indication of risk of a tilapia becoming infected by Streptococcus iniae comprising, methods of producing broodstock, offspring or eggs using so selected tilapia, all optionally using DNA polymorphisms located on linkage group 8 of the tilapia genome.

The invention discloses application of elaifolin in preparation of a medicine for resisting streptococcus suis, and belongs to the field of microbial infectious diseases and medicines. The invention finds that the elaifolin can efficiently inhibit and kill a plurality of serotype streptococcus suis and obviously inhibit or remove biological membranes of the streptococcus suis. The elaifolin can be applied to preparation of anti-streptococcus suis bacteriostasis and sterilization medicines, medicines for treating streptococcus suis infection and medicines for inhibiting or removing streptococcus suis biological membranes. According to the application disclosed by the invention, new medicinal value of the elaifolin is found, and a new prevention and treatment strategy is provided for streptococcus suis drug resistance and biofilm infection; the elaifolin can efficiently act on the multi-drug-resistant streptococcus suis, and a new direction is provided for relieving antibiotic drug resistance crisis.

The invention is applicable to the technical field of gene engineering, and is characterized in that a streptococcus zooepidemicus ATCC 35246 strain is used as a parent strain, and a pSET4S temperature-sensitive suicide gene knockout plasmid is utilized to knock out pyrroline-5-carboxylic acid reductase gene (proC), so that a streptococcus zooepidemicus gene deleted strain ATCC 35246 delta proC is obtained. The deletion strain has low toxicity, and when the mutant strain is used for immunizing a mouse in a large dose of viable bacteria, the titer of an antibody in the mouse can be obviously increased, and targeted immune protection is successfully established; the ATCC 35246 delta proC is convenient to prepare, low in cost and simple to culture, does not need other complex treatment when being used as a vaccine, and can be used after being adjusted to a corresponding concentration after bacteria washing. A result of an immune experiment on a mouse shows that the vaccine can effectively stimulate the immune level of an animal body and resist streptococcus zooepidemicus infection, and the deletion strain is high in safety and remarkable in immune protection effect in the mouse and has the potential of serving as a streptococcus zooepidemicus live vaccine.

The application relates to application of lactococcus lactis in a composition for inhibiting streptococcus pyogenes and angina streptococcus and a product, and belongs to the field of microbial technology. The technical problem to be solved is to provide application of lactococcus lactis in preparation of a composition for inhibiting streptococcus pyogenes and angina streptococcus or treating tumors, and the technical solution points are that the lactococcus lactis is applied in preparation of the composition for inhibiting streptococcus pyogenes and angina streptococcus. The lactococcus lactis OA56 of the application can efficiently inhibit streptococcus pyogenes and angina streptococcus, has low ability of forming a biological membrane, shows strong adhesion to oral epithelial cells and hydroxyapatite, can effectively relieve clinical symptoms caused by streptococcus pyogenes infection, reduce inflammation reaction of gastric epithelial cells induced by angina streptococcus infection, and can treat or assist in treating angina streptococcus related tumors.

The present invention relates to novel immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), and uses of the novel immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates). The immunogenic compositions of the present invention will generally comprise at least one glycoconjugate from Streptococcus pneumoniae serotypes that are not found in Prevnar, Synflorix and / or Prevnar 13. The invention also relates to vaccination of human individuals, particularly infants and elderly people, against Streptococcus pneumoniae infection using the novel immunogenic compositions.

An immunogenic complex comprising i) an amino acid sequence of an N-terminal region of a group B Streptococcus surface protein selected from the group consisting of: a first amino acid sequence having at least 98%, such as 99%, identity to SEQ ID NO: 16 and a length of 172 amino acids to 178 amino acids; a second amino acid sequence having at least 98%, such as 99%, identity to SEQ ID NO: 18 and a length of 167 amino acids to 173 amino acids; and a third amino acid sequence consisting of SEQ ID NO: 20; and ii) a capsular polysaccharide, is provided. An immunogenic product, a vaccine, and the immunogenic complex, the immunogenic product or the vaccine for use in a method of preventing or treating a group B Streptococcus infection, are also provided.

The present invention is directed to particular monoclonal antibodies and fragments thereof that find use in the detection, prevention and treatment of Streptococcus pneumoniae infections. In particular, these antibodies may kill Streptococcus pneumoniae or limit the replication of Streptococcus pneumoniae. Also disclosed are improved methods for producing such monoclonal antibodies.

The application relates to the fields of molecular biology and fish breeding, in particular to application of a specific target sgRNA for knocking out an NSD2 gene in construction of a streptococcus-resistant tilapia strain, and discloses a method for knocking out the NSD2 gene in the tilapia based on CRISPR / Cas9 technology and constructing the streptococcus-resistant tilapia strain. The tilapia with the knocked-out NSD2 gene has stronger resistance to streptococcus infection, and the survival rate is obviously improved when the tilapia is infected with streptococcus.

The invention discloses preparation and application of an Fc synergistic tilapia mossambica streptococcus bigeminy nanocellulose immersion vaccine, and belongs to the technical field of biology. The amino acid sequence of the recombinant protein rSSF is as shown in SEQ ID NO. 1. The invention also discloses a preparation method of a bigeminy subunit nano-carrier immersion vaccine prepared from the bigeminy recombinant protein. The invention also discloses an immune protection effect of the bivalent subunit vaccine on tilapia mossambica to resist streptococcus infection. According to the bivalent subunit vaccine disclosed by the invention, the serum antibody level of tilapia is remarkably improved, the death rate of tilapia infected with streptococcus agalactiae and streptococcus iniae is remarkably reduced, and the bivalent subunit vaccine has a relatively good immune protection effect on tilapia against streptococcus infection and can be used as a potential candidate vaccine for tilapia against streptococcus infection; a new thought and an effective choice are provided for immune prevention and control of tilapia streptococcosis.

The application belongs to the technical field of genetic engineering, and provides an oahs gene deletion strain and application thereof in prevention of Streptococcus suis type 2 infection.The oahs gene deletion strain, namely SC19-ΔOAHS, has very low virulence and is basically non-toxic.The mutant strain has basically no infection damage to mice when the mice are immunized with a large dose of live bacteria, and the antibody titer in the mice is obviously increased with the aid of an adjuvant, so that the immunoprotection can be successfully established.The immunoprotection established after a normal immunization procedure can help the mice effectively resist the infection of Streptococcus suis type 2, reduce the mortality and bacterial colonization in the body.The preparation method of SC19-ΔOAHS is simple, and the strain can be prepared in a short period of time, is simple to culture, and does not need other complex treatment as a vaccine, and can be used after washing and mixing with an adjuvant.SC19-ΔOAHS has the potential to be used as a live bacteria vaccine against Streptococcus suis infection in pigs.

The invention relates to the technical field of aquaculture, in particular to nile tilapia hepcidin as well as a preparation method and application thereof and a bacteriostatic agent. The amino acid sequence of the nile tilapia hepcidin is as shown in SEQ ID No.1, and the nile tilapia hepcidin can inhibit streptococcus agalactiae and / or aeromonas hydrophila. According to the method, the nile tilapia hepcidin can be simply, conveniently and efficiently purified, in-vitro experiments prove that the nile tilapia hepcidin can inhibit proliferation of pathogenic bacteria, and in-vivo experiment research results prove that the hepcidin can remarkably improve the streptococcus infection resistance of tilapia.

The invention relates to the field of molecular biology and fish breeding, in particular to application of a specific target sgRNA for knocking out an NSD2 gene in the aspect of constructing an anti-streptococcus tilapia strain, and further discloses a method for knocking out the NSD2 gene in tilapia and constructing the anti-streptococcus tilapia strain based on a CRISPR / Cas9 technology. Compared with the wild tilapia with the NSD2 gene knocked out, the tilapia with the NSD2 gene knocked out has higher capability of resisting streptococcus infection bacteria, and the survival rate is obviously improved when the tilapia is infected with streptococcus.

The present invention discloses a porcine monoclonal antibody against the SzM protein of Streptococcus zooepidemicus and its application. Using genetic recombination technology, a murine monoclonal antibody with excellent efficacy in preventing or treating S. zooepidemicus infection was porcine-derived. The resulting chimeric antibody replaces the constant region of the murine antibody with that of the porcine antibody, thus avoiding the common inability of murine antibodies to effectively activate complement and Fc receptor-related immune effects in pigs. This antibody is highly effective in treating S. zooepidemicus infection in pigs, providing a new and effective biological product for the clinical prevention and treatment of S. zooepidemicus infection in pigs.